Related Experiment Video
Updated: Jan 22, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after
Goran Marinković1, Helena Grauen Larsen2, Troels Yndigegn2
1Department of Clinical Sciences Malmö, Lund University, CRC 91:12, Jan Waldenströms gata 35, SE-214 28, Malmö, Sweden.
Insights
Blocking S100A9 reduces inflammation and improves heart function after myocardial infarction (MI). This approach may help patients with acute coronary syndrome (ACS) and prevent heart failure (HF).
Area of Science:
- Immunology
- Cardiology
- Molecular Biology
Background:
- Neutrophils play complex roles in myocardial infarction (MI), with underlying pathways not fully understood.
- S100A8/A9, a neutrophil-derived alarmin, is released into circulation post-myocardial ischemia, indicating its potential role in MI pathogenesis.
- High S100A8/A9 levels in acute coronary syndrome (ACS) patients correlate with poorer cardiac function and increased heart failure (HF) risk.
Purpose of the Study:
- To investigate the role of S100A8/A9 in the innate immune response to myocardial infarction (MI).
- To evaluate the therapeutic potential of blocking S100A9 in preclinical models of MI.
Main Methods:
- Analysis of plasma S100A8/A9 levels in 524 acute coronary syndrome (ACS) patients, correlating with cardiac function and heart failure (HF) hospitalization.
- Pharmacological blockade of S100A9 using ABR-238901 in wild-type mice subjected to permanent coronary artery ligation (MI).
- Assessment of immune cell dynamics, cardiac function (left ventricular ejection fraction, cardiac output), and inflammatory markers in treated versus untreated MI mice, including an ischemia/reperfusion model.
Main Results:
- In ACS patients, elevated S100A8/A9 was linked to reduced left ventricular ejection fraction (EF) at 1 year and higher HF hospitalization rates.
- S100A9 blockade in mice inhibited bone marrow stem cell proliferation and myeloid cell egress, reducing cardiac neutrophils and macrophages.
- Treatment with ABR-238901 significantly improved cardiac function, including left ventricular EF and cardiac output, in murine MI and ischemia/reperfusion models.
Conclusions:
- Short-term S100A9 blockade effectively reduces inflammation and enhances cardiac function in experimental models of myocardial infarction (MI).
- The findings suggest that excessive S100A8/A9 release contributes to adverse outcomes in MI and ACS.
- S100A9 blockade presents a promising therapeutic strategy to improve prognosis in patients with acute coronary syndrome (ACS).
Aims:
Neutrophils have both detrimental and beneficial effects in myocardial infarction (MI), but little is known about the underlying pathways. S100A8/A9 is a pro-inflammatory alarmin abundantly expressed in neutrophils that is rapidly released in the myocardium and circulation after myocardial ischaemia. We investigated the role of S100A8/A9 in the innate immune response to MI.
Methods And Results:
In 524 patients with acute coronary syndrome (ACS), we found that high plasma S100A8/A9 at the time of the acute event was associated with lower left ventricular ejection fraction (EF) at 1-year and increased hospitalization for heart failure (HF) during follow-up. In wild-type C57BL/6 mice with MI induced by permanent coronary artery ligation, treatment with the S100A9 blocker ABR-238901 during the inflammatory phase of the immune response inhibited haematopoietic stem cell proliferation and myeloid cell egression from the bone marrow. The treatment reduced the numbers of neutrophils and monocytes/macrophages in the myocardium, promoted an anti-inflammatory environment, and significantly improved cardiac function compared with MI controls. To mimic the clinical scenario, we further confirmed the effects of the treatment in a mouse model of ischaemia/reperfusion. Compared with untreated mice, 3-day ABR-238901 treatment significantly improved left ventricular EF (48% vs. 35%, P = 0.002) and cardiac output (15.7 vs. 11.1 mL/min, P = 0.002) by Day 21 post-MI.
Conclusion:
Short-term S100A9 blockade inhibits inflammation and improves cardiac function in murine models of MI. As an excessive S100A8/A9 release is linked to incident HF, S100A9 blockade might represent a feasible strategy to improve prognosis in ACS patients.
More Related Videos
Related Concept Videos
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Response II: Inflammatory Exudate and Tissue Repair
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
Inflammatory Response I: Vascular and Cellular
Neuromuscular Junction And Blockade
Long-term Depression
Feedback Inhibition

